A preliminary clinical trial to evaluate 64 Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer
Conclusions64Cu-NOTA-Trastuzumab showed a specific uptake at the HER2-expressing tumors, thus making it a feasible and safe monitoring tool of HER2 tumor status in patients with breast cancer.Trial registrationCRIS, KCT0002790. Registered 02 February 2018,https://cris.nih.go.kr
Source: EJNMMI Research - Category: Radiology Source Type: research
More News: Bladder Cancer | Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Clinical Trials | Heart | HER2 | Herceptin | Liver | PET Scan | Radiology | Study | Urology & Nephrology